INTRODUCTION: Peripheral neuropathy is the most common neurological complication of human immunodeficiency virus (HIV) infection but is widely under-diagnosed in resource-limited settings. We investigated the utility of screening tools administered by nonphysician healthcare workers (HCW) and quantitative sensory testing (QST) administered by trained individuals for identification of moderate/severe neuropathy. METHODS: We enrolled 240 HIV-infected outpatients using 2-stage cluster randomized sampling. HCWs administered the several screening tools. Trained study staff performed QST. Tools were validated against a clinical diagnosis of neuropathy. RESULTS: Participants were 65% women, mean age 36.4 years, median CD4 324 cells/μL. A total of 65% were taking antiretrovirals, and 18% had moderate/severe neuropathy. The screening tests were 76% sensitive in diagnosing moderate/severe neuropathy with negative predictive values of 84-92%. QST was less sensitive but more specific. CONCLUSIONS: Screening tests administered by HCW have excellent negative predictive values and are promising tools for scale-up in resource-limited settings. QST shows promise for research use.
INTRODUCTION:Peripheral neuropathy is the most common neurological complication of humanimmunodeficiency virus (HIV) infection but is widely under-diagnosed in resource-limited settings. We investigated the utility of screening tools administered by nonphysician healthcare workers (HCW) and quantitative sensory testing (QST) administered by trained individuals for identification of moderate/severe neuropathy. METHODS: We enrolled 240 HIV-infected outpatients using 2-stage cluster randomized sampling. HCWs administered the several screening tools. Trained study staff performed QST. Tools were validated against a clinical diagnosis of neuropathy. RESULTS:Participants were 65% women, mean age 36.4 years, median CD4 324 cells/μL. A total of 65% were taking antiretrovirals, and 18% had moderate/severe neuropathy. The screening tests were 76% sensitive in diagnosing moderate/severe neuropathy with negative predictive values of 84-92%. QST was less sensitive but more specific. CONCLUSIONS: Screening tests administered by HCW have excellent negative predictive values and are promising tools for scale-up in resource-limited settings. QST shows promise for research use.
Authors: A Pestronk; J Florence; T Levine; M T Al-Lozi; G Lopate; T Miller; I Ramneantu; W Waheed; M Stambuk Journal: Neurology Date: 2004-02-10 Impact factor: 9.910
Authors: J D England; G S Gronseth; G Franklin; R G Miller; A K Asbury; G T Carter; J A Cohen; M A Fisher; J F Howard; L J Kinsella; N Latov; R A Lewis; P A Low; A J Sumner Journal: Neurology Date: 2005-01-25 Impact factor: 9.910
Authors: I S Martina; R van Koningsveld; P I Schmitz; F G van der Meché; P A van Doorn Journal: J Neurol Neurosurg Psychiatry Date: 1998-11 Impact factor: 10.154
Authors: Deanna Cettomai; Judith Kwasa; Gretchen L Birbeck; Richard W Price; Elizabeth A Bukusi; Ana-Claire Meyer Journal: J Neurol Sci Date: 2011-06-11 Impact factor: 3.181
Authors: Jennifer Malon; Eliza Grlickova-Duzevik; James Vaughn; Holly Beaulac; Tyler R Vunk; Ling Cao Journal: J Neuroimmunol Date: 2015-01-27 Impact factor: 3.478
Authors: Yohannes W Woldeamanuel; Peter R Kamerman; Demetri G A Veliotes; Tudor J Phillips; David Asboe; Marta Boffito; Andrew S C Rice Journal: PLoS One Date: 2016-10-20 Impact factor: 3.240
Authors: Getachew Y Yitbarek; Wondimnew D Addis; Fentaw T Dagnaw; Gashaw W Ayehu; Biruk D Melese; Tadeg J Amare; Anemut T Mulu; Wubet A Bayih; Berhanu K Ashagrie; Edgeit A Zewde; Tigabu Munye; Ermias S Chanie; Workneh Ebabu; Sintayehu Asnakew; Getachew Arage; Assefa A Teshome Journal: Mol Pain Date: 2022 Jan-Dec Impact factor: 3.370
Authors: Deanna Saylor; Gertrude Nakigozi; Noeline Nakasujja; Kevin Robertson; Ronald H Gray; Maria J Wawer; Ned Sacktor Journal: Neurology Date: 2017-07-05 Impact factor: 9.910